DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
A phase 1/2 trial of Venetoclax in acute myeloid leukaemia, run by Delta-Fly Pharma, Inc., now recruiting.
Overview
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT06382168 by Delta-Fly Pharma, Inc., with 39 participants planned, started 2024-06-12 and due to reach its primary completion in 2026-03-31. Interventions recorded: DFP-10917 and Venetoclax.
Similar pages
not linked directly; found by shared links- TrialA Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
Shares Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialAB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Shares Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialA Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
Shares Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialIMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Shares Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialA Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Shares Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialStudy of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
Shares Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialSafety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
Shares Venetoclax, Acute myeloid leukaemia and the tag pipeline.
- TrialA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Shares Venetoclax, Acute myeloid leukaemia and the tag pipeline.